secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-12-31T23:59:59+00:00
Accession:  0001193125-25-338318
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio sues Alumis to avoid $3M milestone payment, disputes 'Product' definition under APA
--------------------------------------------------------------------------------

- Filed complaint in Delaware Superior Court seeking declaratory judgment that budoprutug is not a 'Product' under the APA.
- Alumis invoiced $3M milestone payment due Jan 1, 2026 for Phase 2 initiation; Climb denies any obligation.
- Climb dosed first patient in Phase 2 trial on Nov 17, 2025; claims no Royalty-Bearing Patents exist to trigger milestone.
- Dispute centers on interpretation of APA; Climb argues no patents transferred or filed within nine months of closing.
- Climb states it attempted to resolve out of court but Alumis refused.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525338318/0001193125-25-338318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525338318/d19559d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-338318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer